Acute Ischemic Stroke - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 130
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AE2EFC75F88EN
Leaflet:

Download PDF Leaflet

Acute Ischemic Stroke - Pipeline Review, H2 2016
Acute Ischemic Stroke - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Acute Ischemic Stroke - Pipeline Review, H2 2016’, provides an overview of the Acute Ischemic Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
  • The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
  • The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Ischemic Stroke Overview
Therapeutics Development
Pipeline Products for Acute Ischemic Stroke - Overview
Acute Ischemic Stroke - Therapeutics under Development by Companies
Acute Ischemic Stroke - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Ischemic Stroke - Products under Development by Companies
Acute Ischemic Stroke - Companies Involved in Therapeutics Development
AB Science SA
AstraZeneca Plc
Biogen Inc
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Glucox Biotech AB
Jeil Pharmaceutical Co., Ltd.
Lumosa Therapeutics Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Pharmicell Co., Ltd.
PhytoHealth Corporation
Remedy Pharmaceuticals, Inc.
Saneron CCEL Therapeutics, Inc.
Simcere Pharmaceutical Group
Stemedica Cell Technologies, Inc.
Acute Ischemic Stroke - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3K3A-APC - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
AB-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ApTLR-4FT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-IS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DB-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glyburide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPI-289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHN-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rejuveinix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIM-071201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Ischemic Stroke - Dormant Projects
Acute Ischemic Stroke - Discontinued Products
Acute Ischemic Stroke - Product Development Milestones
Featured News & Press Releases
Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199
Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199
Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia
Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
Nov 04, 2015: DiaMedica Provides Corporate Update
Oct 09, 2015: Remedy Pharmaceuticals’ Drug CIRARA™ Cut Death Rates from Severe Stroke by More Than Half
Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting
Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference
Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA
Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA
Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA
Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA
Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures
Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients
Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Ischemic Stroke, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Acute Ischemic Stroke - Pipeline by AB Science SA, H2 2016
Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2016
Acute Ischemic Stroke - Pipeline by Biogen Inc, H2 2016
Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2016
Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2016
Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2016
Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2016
Acute Ischemic Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2016
Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2016
Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2016
Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016
Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2016
Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2016
Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Ischemic Stroke - Dormant Projects, H2 2016
Acute Ischemic Stroke - Dormant Projects (Contd.1), H2 2016
Acute Ischemic Stroke - Dormant Projects (Contd.2), H2 2016
Acute Ischemic Stroke - Discontinued Products, H2 2016
Acute Ischemic Stroke - Discontinued Products (Contd.1), H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Ischemic Stroke, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AB Science SA
AstraZeneca Plc
Biogen Inc
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Glucox Biotech AB
Jeil Pharmaceutical Co., Ltd.
Lumosa Therapeutics Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Pharmicell Co., Ltd.
PhytoHealth Corporation
Remedy Pharmaceuticals, Inc.
Saneron CCEL Therapeutics, Inc.
Simcere Pharmaceutical Group
Stemedica Cell Technologies, Inc.
Skip to top


Acute Heart Failure - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 70 pages

Ask Your Question

Acute Ischemic Stroke - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: